华兴资本控股(01911.HK)发布盈喜2019年上半年利润2610万美元
格隆汇获悉,2019年8月13日,华兴资本控股(01911.HK)发布2019年中期盈利预喜公告,上半年实现利润大幅增长。公告显示,截至2019年6月30日止前六个月,集团上半年共录得利润约2610万美元,实现盈利。
自2018年华兴资本成功登陆香港资本市场,集团旗下投资银行、投资管理、华菁证券三大业务板块均实现快速增长,依托于“全生命周期金融服务”所打造的核心竞争优势,华兴资本投资的微创心脉与南微医学,成为首批登陆科创板的仅有两家生物医疗企业。
日前,华兴资本旗下私募股权基金“华兴新经济基金”宣布已完成第三期人民币基金募资,总募资额超65亿元,超募10余亿元,并吸引到全国社保基金成功入场。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.